All In MedTech

FDA Clearance Tracker · P180035-S031

MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 28, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 28, 2025

Approved

Time to decision

62 days

Received Aug 27, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P180035-S031
Device name
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
Applicant location
Pleasanton, CA
Received
Aug 27, 2025
Decided
Oct 28, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P180035

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code QIT

FDA's approval statement

As written in FDA's record.

Approval of protocol changes to enroll approximately 1000 subjects in PAS002 to achieve at least 4000 patient years total (approximately 2000 per study) with an average follow up of 2-3 years per subject. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P180035.

Source documents

Other decisions for CooperVision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.